Travis Scott Walker
Physician Training at 17 Ave, Denver, CO
License number
Colorado 2706
Issued Date
Jun 23, 2008
Renew Date
Sep 1, 2011
Expiration Date
Aug 31, 2014
Type
Physician Training License
Address
Address
2
12631 E 17Th Ave STE C302, Denver, CO 80045
Denver, CO
Denver, CO
Personal information
See more information about Travis Scott Walker at radaris.comName
Address
Phone
465 Cedar Ave, Springfield, CO 81073
4199 W 53Rd Ave, Denver, CO 80212
Professional information
Travis Walker, Denver CO
Work:
University of Colorado
4200 E 9Th Ave, Denver, CO 80220
4200 E 9Th Ave, Denver, CO 80220
Product And Process For Inhibition Of Biofilm Development
US Patent:
2006003, Feb 9, 2006
Filed:
Aug 4, 2005
Appl. No.:
11/197897
Inventors:
Jerry Nick - Denver CO, US
Travis Walker - Denver CO, US
G. Worthen - Denver CO, US
Travis Walker - Denver CO, US
G. Worthen - Denver CO, US
Assignee:
National Jewish Medical and Research Center - Denver CO
International Classification:
A61K 48/00, A61K 31/7076, A61K 31/7072, A61K 31/522
US Classification:
514044000, 514045000, 514049000, 514263310
Abstract:
Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions.
Product And Process For Inhibition Of Biofilm Development
US Patent:
2008020, Aug 28, 2008
Filed:
May 6, 2008
Appl. No.:
12/115880
Inventors:
Jerry A. Nick - Denver CO, US
Travis S. Walker - Denver CO, US
G. Scott Worthen - Denver CO, US
Travis S. Walker - Denver CO, US
G. Scott Worthen - Denver CO, US
Assignee:
NATIONAL JEWISH MEDICAL AND RESEARCH CENTER - Denver CO
International Classification:
A61K 31/7076
US Classification:
514 44
Abstract:
Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions.
Product And Process For Inhibition Of Biofilm Development
US Patent:
2013022, Aug 29, 2013
Filed:
Oct 12, 2012
Appl. No.:
13/650525
Inventors:
NATIONAL JEWISH HEALTH - , US
Travis S. Walker - Denver CO, US
G. Scott Worthen - Denver CO, US
Travis S. Walker - Denver CO, US
G. Scott Worthen - Denver CO, US
Assignee:
NATIONAL JEWISH HEALTH - Denver CO
International Classification:
A61K 39/395, A61K 45/06
US Classification:
4241351
Abstract:
Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions.